Sorrento Therapeutics, Inc (Nasdaq: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases.
Cancers are genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system. Therefore, we believe any single target therapy is destined to fail. Our approach to cancer therapy is based on the belief that patients will require a multimodal, multipronged approach – targeting a single or diverse set of cellular targets and attacking those on several fronts – simultaneously or sequentially, frequently and relentlessly.
Sorrento’s approach to fighting cancer is made possible by its unique immuno-oncology (“I-O”) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (“G-MAB™”), clinical stage chimeric antigen receptor-T cells (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and an oncolytic virus (“Sephrehvir®”).
To date, we have generated fully human antibodies against many targets, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and CCR2, which are at various stages of development. Our CAR-T programs include clinical stage CEA CAR-T and preclinical stage CD38 CAR-T. Cross-portfolio asset combination therapies are in preclinical stage evaluation for multiple myeloma, metastatic liver cancer, and other adult and pediatric cancers.
Sorrento’s commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (“RTX”) and a next generation lidocaine patch (“ZTlido”). Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido has been approved and is on the market as of October 1, 2018.
We are open to acquire or jointly develop assets and technologies to enhance our I-O platform, to strengthen our development capabilities, and to accelerate drug approvals.